【摘要】 [目的]研究复方消化酶胶囊联合莫沙必利治疗餐后不适综合征(postprandial distress syndrome,PDS)的临床效果。[方法]选取PDS患者90例为研究对象,随机分为对照组与研究组各45例,对照组采用莫沙必利口服,研究组在莫沙必利基础上加用复方消化酶胶囊口服治疗。记录并分析2组患者治疗前后的临床疗效、消化道症状积分、消化道症状发生率、简明健康状况调查表(the SF-36 Health Survey Scales,SF-36)各维度得分及药物不良反应发生率。[结果]治疗前,2组患者的消化道症状积分、消化道症状发生率、SF-36各维度得分比较,差异无统计学意义(P>0.05);治疗后,与对照组比较,研究组总有效[显效24例(53%),有效16例(36%),无效5例(11%)]优于对照组[显效14例(31%),有效17例(38%),无效14例(31%)],2组比较差异有统计学意义(P<0.05)。与对照组比较,研究组消化道症状积分下降,消化道症状发生率下降,SF-36的社会功能、情感职能得分升高(P<0.05)。2组均无药物不良反应发生。[结论]复方消化酶胶囊联合莫沙必利较单用莫沙必利治疗PDS效果显著,且能进一步改善患者的消化道症状和生活质量,值得临床推广应用。更多还原

【Abstract】 [Objective]To investigate the therapeutic effect of Mosapride combined with Compound Digestive Enzyme Capsules on Postprandial Distress Syndrome(PDS).[Methods]A total of 90 patients with PDS were enrolled in the gastroenterology clinic of the first people~,s hospital of Kunming from January to December in 2017,which were selected and randomly divided into control group and study group,with 45 cases in each group.The control group received oral Mosapride treatment,the study group was treated with Mosapride and Compound Digestive Enzyme Capsules treatment.The clinical therapeutic effect,the dyspeptic symptom scores,the incidence rate of the dyspeptic symptoms,every dimension scores of the SF-36 subscale and the incidence rate of medicine-related adverse effects were observed and compared before and after treatment between both groups.[Results]There were no significant differences in dyspeptic symptom scores,the incidence rate of the dyspeptic symptom and every dimension scores of the SF-36 subscale between the two groups before treatment(P>0.05).After treatment,compared with the control group,the curative effect in study group including(24(53%),part effect 16(36%),and no effect 5(11%)were all better than those in control group(obvious effect(14(31%),part effect17(38%)and no effect 14(31%))(P<0.05).The dyspeptic symptom score in study group was significantly lower than that of control group(P<0.05).The SF-36 subscores for social functioning and role-emotional of study group were significantly higher than those of control group(P<0.05).There was no medicine-related adverse effect in both groups.[Conclusion]The clinical therapeutic effect of Mosapride combined with Compound Digestive Enzyme Capsules is markedly better than that of mosapride alone in treatment of PDS,the combination therapy could significantly improve gastrointestinal symptoms and patients’ quality of life,which is worthy of clinical promotion and application.更多还原